Soleno Therapeutics (SLNO) Retained Earnings (2013 - 2026)
Soleno Therapeutics (SLNO) reported Retained Earnings of -$400.0 million for Q1 2026, up 19.35% year-over-year from -$335.1 million in Q1 2025, and down 96485.54% on a QoQ basis from $415000.0 in Q4 2025.
Soleno Therapeutics (SLNO) has 14 years of Retained Earnings data on file, last reported at -$400.0 million in Q1 2026.
- Quarterly Retained Earnings rose 19.35% year-over-year to -$400.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$400.0 million (up 19.35% YoY) and the FY2025 annual result came in at $415000.0, up 100.09% from the prior year.
- Retained Earnings retreated to -$400.0 million in Q1 2026 per SLNO's latest filing, from $415000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $415000.0 in Q4 2025 and bottomed at -$500.7 million in Q2 2025.
- The 5-year median for Retained Earnings is -$254.3 million (2023), against an average of -$252.2 million.
- The widest annual swing landed in 2023, when Retained Earnings slumped 13254900.0%; it then surged 100.09% in 2025.
- Tracing SLNO's Retained Earnings over 5 years: stood at -$237.4 million in 2022, then slipped by 16.42% to -$276.4 million in 2023, then sank by 63.62% to -$452.3 million in 2024, then surged by 100.09% to $415000.0 in 2025, then tumbled by 96485.54% to -$400.0 million in 2026.
- Per Business Quant, the three latest SLNO Retained Earnings figures stand at -$400.0 million (Q1 2026), $415000.0 (Q4 2025), and $360000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | -400.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -400.00 Mn |
| Dec 31, 2025 | 415,000.00 |
| Sep 30, 2025 | 360,000.00 |
| Jun 30, 2025 | -500.74 Mn |
| Mar 31, 2025 | -496.00 Mn |
| Dec 31, 2024 | -452.26 Mn |
| Sep 30, 2024 | -396.30 Mn |
| Jun 30, 2024 | -319.70 Mn |
| Mar 31, 2024 | -106,000.00 |
| Dec 31, 2023 | -276.41 Mn |
| Sep 30, 2023 | -265.10 Mn |
| Jun 30, 2023 | -254.25 Mn |
| Mar 31, 2023 | -245.80 Mn |
| Dec 31, 2022 | -237.42 Mn |
| Sep 30, 2022 | -2,000.00 |
| Jun 30, 2022 | -225.80 Mn |
| Mar 31, 2022 | -219.08 Mn |
| Dec 31, 2021 | -213.36 Mn |
| Sep 30, 2021 | -210.53 Mn |
| Jun 30, 2021 | -202.39 Mn |
| Mar 31, 2021 | -191.40 Mn |
| Dec 31, 2020 | -182.45 Mn |
| Sep 30, 2020 | -179.59 Mn |
| Jun 30, 2020 | -171.05 Mn |
| Mar 31, 2020 | -163.66 Mn |
| Dec 31, 2019 | -157.81 Mn |
| Sep 30, 2019 | -143.18 Mn |
| Jun 30, 2019 | -144.07 Mn |
| Mar 31, 2019 | -134.06 Mn |
| Dec 31, 2018 | -127.03 Mn |
| Sep 30, 2018 | -127.30 Mn |
| Jun 30, 2018 | -124.56 Mn |
| Mar 31, 2018 | -117.50 Mn |
| Dec 31, 2017 | -113.70 Mn |
| Sep 30, 2017 | -108.95 Mn |
| Jun 30, 2017 | -105.17 Mn |
| Mar 31, 2017 | -101.20 Mn |
| Dec 31, 2016 | -98.31 Mn |
| Sep 30, 2016 | -95.70 Mn |
| Jun 30, 2016 | -92.95 Mn |
| Mar 31, 2016 | -89.44 Mn |
| Dec 31, 2015 | -86.25 Mn |
| Sep 30, 2015 | -83.40 Mn |
| Jun 30, 2015 | -80.11 Mn |
| Mar 31, 2015 | -81.99 Mn |
| Dec 31, 2014 | -70.34 Mn |
| Sep 30, 2014 | -63.12 Mn |
| Dec 31, 2013 | -57.10 Mn |